jrnl2331

Publication Venue For

  • MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.  74:3056-3062. 2019
  • Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353.  74:1376-1380. 2019
  • Valaciclovir therapy for herpes encephalitis: Caution advised.  74:1467-1478. 2019
  • Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: Analysis of trends and outcomes.  73:1677-1680. 2018
  • Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK.  72:227-234. 2017
  • Virological efficacy of PI monotherapy for HIV-1 in clinical practice.  71:3228-3234. 2016
  • Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: A retrospective observational cohort study of the Mycoses Study Group (MSG-12).  71:3536-3539. 2016
  • Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.  69:2175-2182. 2014
  • Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.  68:840-851. 2013
  • Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials.  67:2020-2028. 2012
  • Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: A tri-centre cohort study.  64:1282-1290. 2009
  • Treatment of congenital cytomegalovirus infection: Implications for future therapeutic strategies.  63:862-867. 2009
  • Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.  62:1191-1198. 2008
  • De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia.  60:669-672. 2007
  • Activity of posaconazole in the treatment of central nervous system fungal infections.  56:745-755. 2005
  • Bactericidal activity of levofloxacin against Mycoplasma pneumoniae [3].  52:527-528. 2003
  • 2-Alkoxycarbonylaminopyridines: Inhibitors of Mycobacterium tuberculosis FtsZ.  50:111-114. 2002
  • Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp..  45:29-33. 2000
  • Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.  42:811-815. 1998
  • Susceptibility of Chlamydia trachomatis to trovafloxacin.  39:63-65. 1997
  • Susceptibility of Chlamydia trachomatis to trovafloxacin..  39 Suppl B:63-65. 1997
  • New therapeutic approaches to the alphaherpesvirus infections.  39:119-128. 1997
  • Drug discovery for human immunodeficiency virus infection: Conquests and hurdles.  37:151-159. 1996
  • Antiviral resistance: Mechanisms, clinical significance, and future implications.  37:403-421. 1996
  • Efficacy of clarithromycin against Mycoplasma pneumoniae..  27 Suppl A:47-59. 1991
  • Nebulized pentamidine as prophylaxis for pneumocystis carinii pneumonia.  27:153-157. 1991
  • Treatment of human herpesvirus infections with special reference to encephalitis.  14:57-74. 1984
  • Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections: Vidarabine versus acyclovir.  12:105-112. 1983